Topic Highlight
Copyright ©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2007; 13(1): 125-140
Published online Jan 7, 2007. doi: 10.3748/wjg.v13.i1.125
Figure 1
Figure 1 HBsAg seroconversion occurs more frequently on HBV gentoype “A” compared to the other Genotypes. Date given in percent (%). Adapted from Lau GK, et al. N Engl J Med 2005.
Figure 2
Figure 2 Pre-emptive lamivudine is associated with lower frequency and lower severity of hepatitis during chemotherapy. Date given in percent (%). Adapted from Li YH, et al. Cancer 2006.
Figure 3
Figure 3 Viral load reduction at the end of treatment and at 24 wk follow-up in the different treatment arms. Adapted from Lau GK, et al. N Engl J Med 2005.
Figure 4
Figure 4 Different response pattern on famciclovir. Adapted from Tillmann HL et al. Hepatology 1998.
Figure 5
Figure 5 Improvement on famciclovir in a patient with continuous deterioration prior to initiation of famciclovir therapy. Arrow indicates start of famciclovir, where after Bilirubin slowly normalised, and both Quick test (Marker for impaired clotting function) and cholinesterase (CHE) stabilised indicating stabilisation of liver function. (unpulished).
Figure 6
Figure 6 Reduction in HBV-DNA, as well as histological improvement in inflammation and fibrosis according to the Knodell score after 48 wk therapy with 10, 30 mg ADV. Adapted from Marcellin P, et al. N Engl J Med 2003.
Figure 7
Figure 7 Prevalence of resistance on different antivirals, up to 2 (A) and up to 5 (B) year data.